1. Home
  2. BBW vs ATXS Comparison

BBW vs ATXS Comparison

Compare BBW & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBW
  • ATXS
  • Stock Information
  • Founded
  • BBW 1997
  • ATXS 2008
  • Country
  • BBW United States
  • ATXS United States
  • Employees
  • BBW N/A
  • ATXS N/A
  • Industry
  • BBW Recreational Games/Products/Toys
  • ATXS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBW Consumer Discretionary
  • ATXS Health Care
  • Exchange
  • BBW Nasdaq
  • ATXS Nasdaq
  • Market Cap
  • BBW 554.5M
  • ATXS 584.1M
  • IPO Year
  • BBW 2004
  • ATXS 2015
  • Fundamental
  • Price
  • BBW $43.43
  • ATXS $9.55
  • Analyst Decision
  • BBW Strong Buy
  • ATXS Strong Buy
  • Analyst Count
  • BBW 3
  • ATXS 5
  • Target Price
  • BBW $54.33
  • ATXS $28.00
  • AVG Volume (30 Days)
  • BBW 337.9K
  • ATXS 340.4K
  • Earning Date
  • BBW 12-05-2024
  • ATXS 11-13-2024
  • Dividend Yield
  • BBW 1.84%
  • ATXS N/A
  • EPS Growth
  • BBW 8.16
  • ATXS N/A
  • EPS
  • BBW 3.79
  • ATXS N/A
  • Revenue
  • BBW $495,235,000.00
  • ATXS N/A
  • Revenue This Year
  • BBW $2.56
  • ATXS N/A
  • Revenue Next Year
  • BBW $2.52
  • ATXS N/A
  • P/E Ratio
  • BBW $11.48
  • ATXS N/A
  • Revenue Growth
  • BBW 2.76
  • ATXS N/A
  • 52 Week Low
  • BBW $21.24
  • ATXS $5.88
  • 52 Week High
  • BBW $47.01
  • ATXS $16.90
  • Technical
  • Relative Strength Index (RSI)
  • BBW 61.16
  • ATXS 41.21
  • Support Level
  • BBW $40.93
  • ATXS $9.40
  • Resistance Level
  • BBW $43.09
  • ATXS $9.99
  • Average True Range (ATR)
  • BBW 2.35
  • ATXS 0.58
  • MACD
  • BBW 0.27
  • ATXS -0.01
  • Stochastic Oscillator
  • BBW 63.02
  • ATXS 9.32

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Share on Social Networks: